INM
InMed Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.75
+4.17%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -24.8%
- EBIT
- -28.5%
- EPS
- +55.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -99.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +815.8%
- EBITDA
- -26.6%
- EBIT
- -25.0%
- Net income
- -53.9%
- EPS
- +62.7%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026